Earlier this month, Talvey received an accelerated approval as a weekly or biweekly subcutaneous therapy by the US Food and Drug Administration (FDA) as fifth-line therapy for refractory or relapsed multiple myeloma in adults. Image Credit: JHVEPhoto / Shutterstock.

Janssen’s Talvey (talquetamab-tgvs) has been approved by the European Commission as a fourth-line treatment for refractory or relapsed multiple myeloma in adult patients.

Talvey is a bispecific antibody targeting T-cell CD-3 receptors and G protein-coupled receptor class C group 5 member D (GPRC5D). It was awarded the Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) in January 2021.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Earlier this month, it received an accelerated approval as a weekly or biweekly subcutaneous therapy by the US Food and Drug Administration (FDA) as fifth-line therapy for refractory or relapsed multiple myeloma in adults.

Similar to its FDA approval, the European approval is based on Phase I/II data from the MonumenTAL-1 study (Phase I – NCT03399799; Phase II – NCT04634552), reporting a very good partial response (VGPR) or better response in 60.8% of the patients over a 12.7-month period with 0.8mg/kg of Talvey.

The response statistics were worse with a 0.4mg/kg dose at 18.8 months of follow-up, with 59.5% of patients achieving a VGPR or better. For patients who had received CAR-T cell therapy as a prior multiple myeloma treatment, a VGRP or better response was seen in 54.9% of the patients over a 14.8-month follow-up period.

See Also:

The commonly observed adverse events include cytokine release, dysgeusia, hypogammaglobulinemia, nail disorders, and weight loss.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The European Commission also recently approved a reduced dosing frequency of 1.5mg/kg every two weeks (Type II variation) in multiple myeloma for Janssen’s other bispecific antibody, Tecvayli (teclistamab). Patients who have shown a complete response or better with Tecvayli for at least six months are eligible to receive the reduced dosing frequency.

Janssen’s bispecific antibodies are expected to be market leaders, with GlobalData forecasting $1.8bn in global sales for Talvey in 2029.

GlobalData is the parent company of Pharmaceutical Technology.